Mercado cerrado
Silverback Therapeutics/SPRY
13:30
15:10
16:45
18:25
20:00
1D1S1MAHF1A5Y
Acerca de Silverback Therapeutics
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Símbolo
SPRY
Sector
Cotiza en
Industria
Biotecnología
Sede central
Empleados
26
Página web
Métricas de SPRY
BásicoAvanzado
1258 M$
Capitalización
-
PER
-0,47 $
BPA
-
Beta
-
Dividendos
Precio y volumen
Capitalización
1258 M$
Solvencia financiera
Ratio de solvencia
32,823
Test ácido
32,527
Ratio de endeudamiento total
0,074
Eficacia de la gestión
Rendimiento de los activos (TTM)
-14,75 %
Rentabilidad de los fondos propios (TTM)
-19,34 %
Valoración
Ratio precio-ventas (TTM)
2499,037
Ratio precio-valor contable
5,84
Ratio precio-valor contable neto (TTM)
5,84
Ratio precio-flujo de caja libre (TTM)
-28,249
Crecimiento
Variación de los ingresos (TTM)
128,31 %
Variación del beneficio por acción (TTM)
-37,12 %
Qué piensan los analistas de SPRY
Valoración de los Analistas
Calificaciones de analistas (comprar, conservar, vender) para la acción Silverback Therapeutics.
Rendimiento financiero de SPRY
Cuenta de resultados
Ingresos y gastos
TrimestralAnual
Q3 24
Crecimiento intertrimestral
Ingresos
37 mil M$
-39,75 %
Beneficios
45 mil M$
107,52 %
Margen de beneficio
37,65 %
6,78 %
Rentabilidad de SPRY
Beneficios por acción (BPA)
Rentabilidad de la empresa
TrimestralAnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Real
3,69 $
2,85 $
2,45 $
2,42 $
-
Previsto
3,55 $
2,61 $
2,05 $
2,31 $
3,94 $
Sorpresa
3,94 %
9,20 %
19,51 %
4,63 %
-
Noticias de SPRY
TodosArtículosVídeos
![ARS Pharmaceuticals Inc. Might Have Committed Securities Law Violations And The Schall Law Firm Wants Investors To Partake In An Inquiry](/_next/image?url=https%3A%2F%2Fcdn.snapi.dev%2Fimages%2Fv1%2F0%2Fd%2Fpress13-2619452.jpg&w=3840&q=75)
ARS Pharmaceuticals Inc. Might Have Committed Securities Law Violations And The Schall Law Firm Wants Investors To Partake In An Inquiry
Accesswire·hace 13 horas
![EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)](/_next/image?url=https%3A%2F%2Fcdn.snapi.dev%2Fimages%2Fv1%2Fh%2Fo%2Fpress13-2608674.jpg&w=3840&q=75)
EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
GlobeNewsWire·hace 6 días
![A Securities Fraud Inquiry Into ARS Pharmaceuticals Inc Has Been Opened By The Schall Law Firm And Shareholders Are Invited To Join](/_next/image?url=https%3A%2F%2Fcdn.snapi.dev%2Fimages%2Fv1%2F3%2Fa%2Fpress6-2607312.jpg&w=3840&q=75)
A Securities Fraud Inquiry Into ARS Pharmaceuticals Inc Has Been Opened By The Schall Law Firm And Shareholders Are Invited To Join
Accesswire·hace 1 semana
Los datos expuestos son meramente indicativos y no se garantiza que sean exactos o completos. El precio de ejecución real puede variar. Rentabilidades pasadas no son indicativas de resultados futuros. Tu rentabilidad puede verse afectada por las fluctuaciones monetarias y las comisiones y gastos aplicables. Capital en riesgo.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.